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Abstract 
Clinical outcomes of patients with diabetes, foot ulceration and peripheral artery 
disease (PAD) are difficult to predict. The prediction of important clinical 
outcomes, such as wound healing and major amputation, would be a valuable tool 
to help guide management and target interventions for limb salvage. Despite  
the existence of a number of classification tools, no consensus exists as to the most 
useful bedside tests with which to predict outcome.  We here present an updated 
systematic review from the International Working Group of the Diabetic Foot, 
comprising 15 studies published between 1980 and 2018 describing almost 6800 
patients with diabetes and foot ulceration.  Clinical examination findings as well 
as six non-invasive bedside tests were evaluated for their ability to predict wound 
healing and amputation.  The most useful tests to inform on the probability of 
healing were skin perfusion pressure ≥40mmHg, toe pressure ≥30mmHg or TcPO2 
≥25mmHg.  With these thresholds, all of these tests increased the probability of 
healing by >25% in at least one study.  To predict major amputation, the most 
useful tests were ankle pressure <50mmHg, ABI <0.5, toe pressure <30mmHg and 
TcPO2<25mmHg, which increased the probability of major amputation by >25%.  
These indicative values may be used as a guide when deciding which patients are 
at highest risk for poor outcomes and should therefore be evaluated for 
revascularisation at an early stage.  However this should always be considered 
within the wider context of important co-existing factors such as infection, wound 
characteristics and other comorbidities. 
 






The presence of peripheral artery disease (PAD) constitutes a significantly 
increased risk of failure to heal and major lower limb amputation in persons with 
diabetes and a foot ulcer (1). PAD is a variable disease in terms of its distribution 
and severity. It is well recognised that patients with diabetes exhibit a different 
pattern of peripheral arterial disease compared to those without diabetes (diffuse, 
distal disease with high prevalence of medial sclerosis and poor collateral 
formation) (2). Once the diagnosis of PAD is established in these patients (2), the 
next step should be assessment of the severity of the perfusion deficit. There are 
a number of validated scoring systems that may be used for classification and 
prognosis of diabetic foot ulcers and almost all incorporate a component relating 
to PAD (3). Typically, subjective bedside evaluations (including assessment of 
pulses or symptoms suggestive of PAD) are combined with non-invasive objective 
tests that can be used for the assessment of the tissue perfusion deficit to inform 
the clinician of the healing potential of the ulcer. Different tests are advised and 
also the extent of the perfusion deficit that should be the threshold for subsequent 
intervention can be a matter of debate. Therefore, it would be useful to be able to 
identify any specific characteristics of PAD that may be associated with poor 
outcomes, in order to help decide whether revascularisation is likely to be 
successful or futile, regardless of strategy. 
The aim of this systematic review is to update our previous review on the 
performance of non-invasive bedside tests to predict outcomes in diabetic foot 
ulceration (4), in order to guide the treating clinician as to the likely outcome and 




Using the Preferred Reporting Items for Systematic Reviews and Meta-analysis 
(PRISMA) guidance (5), we updated our previous systematic review (4), guided 
by a recent consensus document on updating systematic reviews (6) and the 
IWGDF methodology document (7). As a start, the population of interest (P), 
interventions (I), comparators (C) and outcomes (O) were defined, and clinical 
questions (PICOs) were formulated accordingly. These definitions and PICOs were 
reviewed for their clinical relevance by the IWGDF Editorial Board and external 
experts worldwide, from various geographical regions. Final definitions and PICOs 
are integrated within this paper.  
 
We searched the MEDLINE and EMBASE databases for studies relating to the 
prognosis of PAD amongst patients with diabetes and foot ulceration, updating the 
previous search and therefore capturing any new records published between June 
2014 and June 2018 (Appendix A).  Two reviewers independently screened the 
abstracts for inclusion and a third reviewer adjudicated any conflicts.  The full-
text of screened articles was accessed and assessed for inclusion and data were 
then extracted and verified by members of the IWGDF PAD working group. 
 
Inclusion / exclusion criteria 
We included studies that evaluated non-invasive bedside tests in patients with 
diabetes and foot ulceration to predict clinical outcomes such as clinical 
symptoms, signs or an objective index measure of PAD.  Studies were excluded if 
they evaluated patients with an intact foot or assessed only demographic factors 
as predictors of outcomes. The clinical outcomes of interest were wound healing 
and major amputation.   
Investigations of reduced perfusion that were considered included clinical 
examination, ankle and toe pressures / indices, Doppler waveform analysis, 
transcutaneous oxygen pressure (TcPO2), laser Doppler imaging, pole test and 
objective measures of skin temperature.  These tests were considered if reported 
with a cut-off value or threshold to predict outcomes. Gold standard tests used to 
diagnose PAD included magnetic resonance angiography (MRA), computed 
tomographic angiography (CTA) and digital subtraction angiography (DSA). 
Studies with insufficient information on the revascularisation status of the cohort 
during follow up were excluded, as were those with <6 months duration of follow 
up.  Studies that did not report data allowing the calculation of sensitivity and 
specificity (and associated likelihood ratios) were also excluded. 
 
Primary endpoints 
The primary endpoints for this review were positive and negative likelihood ratios 
(PLR and NLR) for healing and major amputation.  Likelihood ratios are used to 
express a change in odds of reaching an outcome, in the context of a known pre-
test probability of disease (ie knowledge or estimation of the prevalence of disease 
in the studied population). The PLR gives the change in odds of experiencing an 
outcome if the test is positive, whereas the NLR expresses a change in odds of 
experiencing an outcome if the test is negative.   
A PLR or NLR of 1.0 means that the test does not change the probability of the 
outcome over and above the pre-test probability and therefore is not a useful 
prognostic test.  As a general rule of thumb, a test is considered to have very good 
performance if PLR ≥10 (representing an increased probability of the specified 
outcome by around 45% in the presence of a positive test result) and NLR≤0.1 
(representing a decrease in the probability of the specified outcome of around 
45% in the presence of a negative test result) (8) (9).  The higher the PLR, the 
greater the ability of the test to rule in the outcome of interest, whilst a smaller 
NLR reflects better ability of the test to rule out the outcome. The practical 
application of this is to identify the most useful bedside tests that will inform the 
healthcare professional as to the probability, or not, of the patient experiencing 
healing or major amputation (Table 1). 
Data were analysed as univariable associations of PAD markers with clinical 
outcome, due to the many factors affecting the likelihood of healing and major 
amputation. Whilst we recognise the importance of other confounding factors on 
clinical outcome, we lacked individual patient data from which to adjust our 
analyses for them.   
 
Data extraction and quality assessment 
Data extraction was undertaken and independently verified by two reviewers.  
Methodological quality was assessed using the Quality in Prognosis Studies 
(QUIPS) tool. Studies were rated as low quality (0), in which case they were 
excluded, acceptable (+) or high quality (++).  The populations evaluated were 
heterogeneous, as were the outcomes reported and prognostic tests used, 
therefore no meta-analysis was undertaken.  Instead, measures of test 
performance were presented for each prognostic test used and summarised 
within and across studies.  Where not explicitly reported, sensitivity / specificity, 
positive likelihood ratio (PLR) and negative likelihood ratio (NLR) were calculated 
from the available data and reported in the data table.  The median and range of 
summary statistics, including estimates of predictive performance, are presented, 
stratified by index test and population studied. 
 
Evidence statements 
We drew conclusions for each intervention based on the strength of the available 
evidence and summarised this as evidence statements with accompanying 
assessment of the quality of the evidence, according to GRADE (10). 
 
Results   
Search results 
In the search performed for our previous systematic review 9476 studies were 
screened (published between 1980-2014), which resulted in total of 11 
observational studies reporting data from 5890 patients with diabetes and foot 
ulcer. Our updated search included papers published between June 2014 and June 
2018.  Our initial search yielded 9068 titles, of which 3 observational studies 
(comprising in excess of 900 patients with diabetes) and 1 systematic review / 
meta-analysis ultimately met the inclusion criteria. Therefore, after including 11 
studies from our previous review (4), a total of 15 studies were included in the 
qualitative data table for this updated review, comprising almost 6800 patients 
(Table 2).  One of these studies was the systematic review of Wang et al. from 2016 
that had less stringent inclusion criteria and that had a larger number of studies 
included compared to the current review. For comparison we included this study 




The mean or median age of the cohort studies ranged between 58 and 76 years, 
whilst the proportion of men was between 57% and 74%.  Thirteen studies 
reported exclusively on patients with diabetic foot ulceration (12), (13) (14) (15) 
(16) (17) (18) (19) (20) (11) (21) (22) (23) , whereas 2 studies included a mixed 
cohort of patients, of which at least 80% of patients had diabetes (24) (25).  One 
study investigated the prognostic performance of PAD measures in patients with 
foot infection and/or ischaemia (Fontaine III/IV) (24).  Severity of ulceration was 
assessed in 6 studies and the proportion of patients with Wagner grade ≥3 ranged 
from 16% to 61%.  Seven studies did not report on ulcer severity (12) (16,25) (18) 
(20) (21) (11).  
 
Revascularisation  
In those studies reporting it, revascularisation rates ranged from 5% to 100%, 
with angioplasty (34%) more frequently used than open revascularisation (21%).  
Four studies excluded patients who underwent revascularisation (14) (16) (18) 
(23).  
 
Prognostic tests evaluated 
Only two studies evaluated the use of clinical examination to predict outcome (24) 
(13).  Ten studies evaluated ABI or ankle pressures (12) (14) (16) (25) (19) (15) 
(11) (22) (21) (23); other measures of perfusion evaluated were toe brachial 
index (TBI) or toe pressures (14) (16) (25) (18) (15) , TcPO2 levels (24) (18) (11) 
(21) (23): , skin perfusion pressure (16) (20), tibial waveform analysis (17) and 
fluorescein toe slope (25).  Two studies provided data on different thresholds of 
the same investigation (18) (15) and 8 compared data on the performance of 
multiple modalities (14) (16) (25) (18) (15) (11,23) (24) (21), allowing direct 
comparison within the same cohorts. 
 
Clinical outcomes 
Table 3 presents clinical outcomes by study.  The rate of primary healing varied 
between 36% and 83%, whilst the rate of major amputation ranged between 3.6% 
and 35%.  The highest rate of major amputation (35%) was reported by Tsai et al, 
who evaluated a high-risk population of patients with diabetic foot ulcer and 
dialysis-dependent end-stage renal failure (17) .   
 
PICO: In a person with diabetes, foot ulceration and PAD, which clinical 
signs, symptoms or non-invasive bedside tests may predict wound healing 
and major amputation? 
 
Non-invasive tests to predict wound healing 
Clinical signs or symptoms  
Two studies evaluated clinical signs or symptoms of PAD as possible predictors of 
clinical outcome (13) (24).  Bunt et al conducted a cohort study that evaluated the 
predictive value for healing of palpable pedal pulses and TcP02 in 147 patients 
(90% of whom had diabetes) with a foot infection or ischaemia, treated with the 
same management protocol in a secondary care setting, (24) .  Healing was defined 
as primary healing or healing after minor amputation or debridement, with or 
without revascularisation. All 44 patients with readily palpable pulses healed 
without revascularisation, suggesting that palpable pulses could be a strong 
predictor of healing.  In the 103 patients with reduced or no pulses the TcPO2 was 
measured, and those patients with TcP02 <30 all underwent revascularisation 
(46%). The presence of palpable pedal pulses in the whole cohort was associated 
with higher likelihood of healing (RR 2.26, 95% CI 2.05-2.49; sensitivity 35%, 
specificity 100%).  The NLR was 0.65, which corresponds to little change in the 
probability of healing if pulses are absent. All patients with palpable pedal pulses 
healed. It should be noted that the risk of bias in this one study on the presence of 
palpable pulses is unclear due to lack of many details. 
 
Elgzyri et al undertook a prospective cohort study of 478 people with DFU who 
had toe pressure <45mmHg or ankle pressure <80mmHg (13) who underwent 
revascularisation (66% endovascular, 34% open surgery).  The primary focus of 
the paper was time to revascularisation, and they reported that patients who 
underwent revascularisation within 8 weeks of referral were more likely to heal 
(HR 1.96; 95% CI, 1.52-2.52, p<0.001).  In addition, those with intermittent 
claudication appeared to have an increased likelihood of healing (HR 1.64; 95% 
CI, .26-2.13; p<0.001). No explanation for this finding was given, however, the 
presence of intermittent claudication does not appear to be a useful prognostic 
measure given a PLR of 1.59 and a NLR of 0.81.  A limitation of this study is that 
the tests were performed in patients with the most severe ischaemia. 
 
Neither of the two aforementioned studies compared clinical examination against 
objective measures of perfusion, hence their accuracy in detecting ischemia is 
unknown.  
 
Ankle pressure or ankle brachial index   
In studies evaluating ankle pressure, using a threshold of >50mmHg produced a 
PLR for wound healing between 1.08 and 1.46, meaning that there is almost no 
improvement on the probability of healing when the ankle pressure is above this 
threshold.  Increasing the threshold to ≥70 or ≥80mmHg improved the PLR to 
2.52-3.24, which represents a minor increase in the probability of healing. 
However, in one study, using a value of ≥70mmHg achieved an NLR of 0.1, 
suggesting that the chance of not healing was increased if the ankle pressure was 
below 70mmHg (25).  Four studies that evaluated ABI (normal defined as 
threshold >0.8, >0.9 or between 0.9 and1.3,) yielded variable results (19) (11) 
(21) (22). The ABI was not strongly predictive of healing (PLR 1.0-3.09; NLR 0.29-
1.0) in two studies (19) (22) as well as in the systematic review of Wang et al (11), 
with poor ability to rule in or rule out the outcomes of interest as reflected by the 
low magnitude of the PLR and NLR (PLR range 1.0-3.09; NLR range 0.29-1.0). 
However, a third study of 564 patients with Wagner grade II or III ulcers found 
ABI >0.9 strongly predictive of healing (PLR 13.83) but with a trade-off for a poor 
NLR (0.6), i.e. the ABI could not predict well who did not heal (23). 
 
Toe pressure  
The use of toe pressure to predict healing was examined at thresholds of 
≥30mmHg in four papers (14) (16) (18) (15) , with a PLR between 1.12 and 5.00; 
the NLR was between 0.28 and 0.88. When the threshold was increased to 
≥45mmHg (18) (15), there was little difference in the magnitude of the PLR (PLR 
2.88 and 4.30).  
 
Skin perfusion pressure 
A threshold skin perfusion pressure of ≥40mmHg was associated with moderately 
good performance for prediction of healing in two studies (PLR 4.86 and 6.40, with 
NLRs of 0.03-0.40) (20) (16).  
 
Transcutaneous oxygen pressure 
At a threshold of 22.5-30mmHg, TcPO2 was shown to have a moderate 
performance for prediction of healing in three studies (PLR 10.63, 4, and 1.21 NLR 
0.16, 0.33 and <0.1) (18) (23) (21). The systematic review of Wang reported a 
pooled PLR of 5.14 and a NLR of 0.33 using a TcPO2 cut-off < 30 mmHg (11). 
 
Fluorescein toe slope 
Fluorescein angiography may be used as a marker of tissue perfusion, as the 
distribution of fluorescence in the skin after intravenous administration of 
fluorescein is related to the distribution of blood flow.  One study evaluating the 
use of fluorescein toe slope in comparison with ankle pressure >70mmHg or toe 
pressure >20mmHg (25) found a similar performance when comparing the three 
tests. For a toe slope of <18 units, the PLR was 2.47 and NLR was 0.09.  This means 
that it only has a minor ability to predict healing but may be useful to indicate 
those that will not heal. 
 
Non-invasive tests to predict major lower limb amputation 
Eight studies (including the systematic review of Wang et al) evaluated non-
invasive bedside tests for the prediction of major amputation (amputation of the 
leg proximal to the ankle), Table 5 (25) (19) (15) (17) (11) (21) (22) (23). 
 
Ankle pressure or ankle brachial index 
Two studies evaluated ankle pressures as predictors of major amputation 
(amputation of the leg proximal to the ankle) (25) (15).  In one study, ankle 
pressures of <50mmHg and <80mmHg were compared within the same cohort.  
When the lower threshold was used, there was increased specificity (84% vs 79%) 
but this was at the cost of reduced sensitivity (20% vs 39%). The higher threshold 
of <80mmHg performed slightly better (PLR 1.89 vs 1.25; NLR 0.77 vs 0.95) (15) 
with regards to the prediction of major amputation.  Another study used a cut-off 
value of <70mmHg, which gave an improved performance with a PLR of 4.28, 
which corresponds with an increase in the likelihood of major amputation of 
>25% (25). 
One study evaluated ankle brachial index (ABI) as a predictor of major amputation 
and concluded that a threshold of ABI <0.6 performed best, with a PLR of 68 
corresponding to a very high increased probability of major amputation. The NLR 
was 0.32. This prospective study was performed in a cohort of 564 patients in 
India with diabetic foot ulceration of which only 15% had PAD (defined as ABI 
<0.9 or TcP02<40) (23). In the systematic review of Wang et al (11) a threshold 
<0.8 was used, which yielded a relatively small change in the probability of limb 
amputation (PLR 1.93-3.5; NLR 0.39-0.66).   
When in one study the combination of an ankle pressure <50mmHg or an ABI <0.5 
was evaluated, this was shown to have strong ability to both rule in and rule out 
major amputation in a further study (19), with a PLR of 8.24, representing a 40% 
increased probability of amputation,  and with a NLR of 0.14. 
 
Toe pressure 
A study by Gershater et al compared toe pressure thresholds of <30mmHg and 
<45mmHg and found them broadly equivalent in predicting major amputation 
(PLR 2.64 and 2.05) (15).  When this threshold was reduced to <20mmHg in a 
different study (25), the PLR was improved to 3.18, which increases the 
probability of amputation by around 15-20%, but with a corresponding NLR of 
0.49, reflecting poor ability to rule out major amputation. 
 
Transcutaneous oxygen pressure 
In the two studies on TcPO2 , a value < 22.5- 25 mmHg had a PLR of 3.41 and >10, 
with a NLR of 0.51 and 0.25 (21) (23). In the systematic review of Wang et al, the 
pooled PLR and NLR were 1.79 and 0.43, respectively  (11). 
 
Fluorescein toe slope 
In a study of 83 patients with foot ulcers, fluorescein toe slope (the rate of 
fluorescence on the hallux during the first 10 seconds of its appearance on the toe) 
<18 unit was found to have a reasonable prognostic accuracy (PLR 4.04, NLR 
0.49), which corresponds to an increase in likelihood of major amputation of 
around 25% (25). This was comparable to the use of ankle pressure (<70mmHg) 
and toe pressure (<20mmHg) in the same study. 
 
Doppler waveform analysis 
One study evaluated the use of Doppler waveform analysis and found that the 
absence of flow or monophasic signal in the below-knee vessels modestly 
increased the probability of amputation (PLR 2.18) (17). This was less informative 
than other tests such as fluorescein toe slope <18 units, toe pressure <20mmHg 
and combined ABI <0.9 and ankle pressure <50mmHg. 
 
Evidence statement: The following tests increased the probability of healing of a 
diabetic foot ulcer  by >25% in at least one study: a toe pressure ≥30mmHg, a 
TcPO2 ≥  22.5-25 mmHg and a skin perfusion pressure ≥40mmHg,   
 
Quality of evidence: Moderate, not all studies obtained consisted results 
 
Evidence statement: The following tests increased in at least one study the 
probability of a major amputation in a patient with a diabetic foot ulcer by >25%: 
ankle pressure <70mmHg, ABI <0.6, TcPO2< 25mmHg and a fluorescein toe slope 
<18 units. The combination of ABI <0.5 and ankle pressure <50mmHg improved 
this to around 40% in one study. 
 
Quality of the evidence: Moderate, not all studies obtained consistent results 
 
Discussion 
This updated systematic review evaluates the performance of six non-invasive 
prognostic bedside tests (in addition to common clinical examination findings) to 
predict the likelihood of wound healing or major amputation in patients with 
diabetes and foot ulceration.  Whilst we know that the presence of PAD increases 
the risk of poor outcomes in a patient with foot ulceration, only a subset of patients 
will experience them. Although major advances have been made in treating PAD 
in patients with DFU, both endovascular and open surgical revascularisation 
procedures are not without risk. A prognostic test that assesses the severity of the 
perfusion deficit whilst also informing healthcare professionals (and patients) 
about the probability of a specified clinical outcome (such as healing or major 
amputation) would be a useful tool in clinical decision making.  It is often not 
feasible, or necessary, to perform vascular imaging on every patient with a foot 
ulcer and diabetes when they first present. However, it would be useful for the 
treating clinician to identify those patients with a higher probability of healing 
without revascularisation, in order to pursue a conservative approach in the first 
instance.  Similarly, if a patient is identified as having an unacceptably high 
probability of major amputation, urgent investigation and revascularisation 
should be considered.   
 
The data reviewed here were heterogeneous, as were the patient cohorts, with 
probably important differences in wound and patient characteristics, and it is not 
surprising that no single test performed consistently well across these studies.  
The presence of palpable foot pulses was associated with future healing in one 
study but this report was difficult to interpret and the absence of foot pulses does 
not necessarily mean that an ulcer will not heal, stressing the importance of non-
invasive tests. The most useful tests to inform on the probability of healing were 
skin perfusion pressure ≥40mmHg, toe pressure ≥30mmHg or TcPO2 ≥25mmHg.  
With these thresholds, all of these tests increased the probability of healing by 
>25% in at least one study. When such results are obtained, it would be reasonable 
to undertake an initial period of conservative management, particularly if the 
patient has a relatively high pre-test probability of healing (e.g. a superficial 
wound with no evidence of infection).  
 
Although sometimes thought to be the reverse of each other, wound healing and 
major amputation are different outcomes and can have different determinants. 
When considering tests to predict major amputation, the most useful were ankle 
pressure <50mmHg, ABI <0.5, toe pressure <30mmHg and TcPO2<25mmHg.  In 
addition, fluorescein toe slope <18 units performed to a similar standard. Again, 
all of these tests increased the probability of major amputation by around 25% in 
at least one study, and the combination of ABI <0.5 and ankle pressure <50mmHg 
improved this to around 40%.  Therefore, patients in whom these criteria are met 
could be considered at higher risk of limb loss when compared to those with a less 
severe perfusion deficit. These patients should be considered for urgent vascular 
imaging and revascularisation at an early stage of the clinical management of their 
DFU.  However, the use of ABI and ankle pressures in this cohort should be 
interpreted with a degree of caution.  It is well recognised that patients with a 
supra-normal ABI are at increased risk of mortality, and that a high ABI represents 
incompressible arteries rather than high intraluminal pressure (26) (27) (28).   It 
is estimated that 30-40% of patients with diabetes have significant medial artery 
calcification (29) (30) which leads to incompressible vessels and abnormally high 
ABI.  Only some of the studies assessing ABI or ankle pressures excluded patients 
with abnormally high readings suggestive of incompressible vessels.  For example, 
the systematic review by Wang et al defined abnormal ABI as <0.8, whereas Bunt 
and colleagues recognised ABI >1.3, closing pressure >200 mmHg or 
incompressible vessels to be abnormal and a sign of mediasclerosis (11). 
However, the important finding of our review was that low ABI or ankle pressure 
were useful to predict the likelihood of amputation, but normal results were not 
useful when predicting the likelihood of wound healing.  
 
The use of a major amputation as an endpoint has certain limitations, as it is a 
procedure and not an endpoint in the strict sense. The reason for the procedure is 
rarely indicated – for example, it may be required for sepsis control in a patient in 
whom revascularisation has been successful, or conversely for a patient with 
minor tissue loss but intractable pain due to unsuccessful revascularisation or no-
option ischaemia.  Treatment methods and technologies have changed 
substantially since 1980, and there is now in our experience a greater propensity 
to perform minor amputation following revascularisation (including multiple 
attempts) rather than primary major amputation. In addition, patients included in 
a prospective study frequently already have a history of prior foot disease, it is 
therefore impossible to determine where in the disease process an individual 
patient is and frequently there is no information whether an intervention prior 
inclusion in a study has been performed. Finally, the occurrence of outcomes such 
as wound healing and major amputation can be affected by the duration of follow 
up, which varied between studies. 
 
In patients with diabetes, PAD and foot ulceration, impaired perfusion is usually 
only one of the factors contributing to the risk of non-healing and amputation, and 
the outcome of the ulcer does not rely simply on improving foot perfusion.  For 
instance, in patients who had a lower extremity bypass because of critical limb 
ischemia (59% had diabetes), more than half of the major amputations during 
follow-up were performed in patients with a patent bypass. (31). There is clearly 
a need for further understanding of the contribution of perfusion deficit to the 
prognosis of patients with a diabetic foot ulcer and the interaction with other local 
and systemic factors. Bedside tests of perfusion should not be used in isolation 
and most guidelines have moved toward multi-factorial tools to assess prognosis, 
which also include other important contributing factors such as infection and 
wound characteristics. Any prognostic test of PAD severity described in this 
review should therefore be combined with the evaluation of infection and wound 
characteristics in order to provide a more meaningful measure of prognosis that 
encompasses all of the relevant components of DFU. These systems, such as the 
WIFi classification, require each domain to be graded according to severity, 
allowing an overall risk category to be calculated as addressed elsewhere in this 
issue (3). In addition, it is recognised that the combination of more than one test 
(ie serial testing) may provide more useful information on the likely prognosis 
than a single test or tests used in isolation (parallel test). However this approach 
was not reported amongst the majority of the studies included here and this lack 
of information is a weakness of our review.  
 
Nevertheless, knowledge of the performance of non-invasive bedside tests to 
predict outcome allows a better understanding of the potential for wound healing 
or the probability of major amputation, and remains a valuable tool for healthcare 
professionals involved in the management of patients with diabetes and foot 
ulceration. However relevant data are limited, heterogeneous and studies are 
often of relatively poor quality.  In order to address this, more effort is required to 
produce well-designed studies, to use standardised data sets and to develop 
international registries, which will more accurately inform on the factors most 
strongly predictive of poor outcomes. Although developed as guidance for 
intervention studies, standards of reporting in this area were formulated by a joint 
team of the IWGDF and European Wound Management Association, which future 




Amongst the 15 studies included in this review, comprising almost 6800 patients 
with a diabetic foot ulcer, the presence of severe perfusion deficit (ankle pressure 
<50mmHg, ABI <0.5, toe pressure <30mmHg and TcPO2<25mmHg) was 
associated with >25% increased risk of major amputation, whilst a better 
perfused foot (skin perfusion pressure ≥40mmHg, toe pressure ≥30mmHg or 
TcPO2 ≥25mmHg) was found to be more likely to heal.  These measures of PAD 
may be used as a guide when deciding management of patients, and the likelihood 
of healing or major amputation can be incorporated into the decision to pursue 
conservative management or a further vascular assessment potentially leading to 
revascularisation. However, these measures should be used in the wider context, 
acknowledging the contribution of other clinical predictors of the outcome of a 
foot ulcer. Further research is required to more accurately evaluate the role of 
bedside tests of PAD in the prognosis of patients with diabetes and foot ulceration. 
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toe pressure <45 
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absence of flow in 
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 ABI >0.8: Complete 
ulcer healing: 
sensitivity 0.48 (95% 
CI 0.36-0.61); 
specificity 0.52 (95% 
CI 0.42-0.63); DOR 
1.02 (95% CI 0.40-
2.65). ABI<0.8: Limb 
amputation: 
sensitivity 0.52 (95% 
CI 0.49-0.54); 
specificity 0.73 (95% 
CI 0.63-0.81); DOR 


















healing and limb 
amputation than 
ABI.  Other 
parameters were 
reported in this 
systematic review 
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here as data not able 
to be pooled. 
0.72 (95% CI 0.61-
0.81); specificity 0.86 
(95% CI 0.68-0.95); 




sensitivity 0.75 (95% 
CI 0.73-0.77); 
specificity 0.58 (95% 
CI 0.52-0.64); DOR 


















with DFU. Mean 
age 76 (69-82), 
69.9% male. CAD 
65.3%, smoking 
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specificity 0.23; PLR 
1.21, NLR 0.33 
 
Sensitivity 0.58, 
specificity 0.83; PLR 
3.41, NLR 0.51 
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categories but the 
























with DFU. Mean 
age 61 (SD 12.8), 
57.7% male.  
39.4% had Wagner III 









(minor 62 in 
and major in 5) 
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 ABI < 0.9 
Odds ratio 9.01 
(3.8, 21.8) 
Sensitivity 0.80, 
specificity 0.69, PLR 




specificity 0.80, PLR 
3.45, NLR 0.39 
 The analysis 
compared the ability 
of 5 different ulcer 
classification 
systems to predict 
amputation. All 
systems had an 
AUROC > 0.8 
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with Wagner II and III 
foot ulcers (no 
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From ROC curves: ABI 
<0.6: Sensitivity 99%, 
Specificity 68% 
PLR 3.09 , NLR 
0.01ome of 
amputation: 
- ABI <0.6: Sensitivity 
68%, Specificity 99% 
TcPO2 <22.5:  
Sensitivity 100%, 
Specificity 75% 




ABI <0.6: Sensitivity 
68%, Specificity 99% 
PLR 68, NLR 0.32 
 
 
TcPO2 <22.5:  
Sensitivity 75%, 
Specificity 100% 
 Techniques for 
measuring ABI and 









healing ulcers at end 
of study period – 
selection bias 
* Only ABI and TcPO2 are included from this study. Other parameters were reported in this paper (eg SPP, TBI, TBP) but are not included here 
as data are not able to be pooled. 
 
Table 3. Event rates for healing and major amputation by study 
Source N (DFU) Population 
Healing 
n (%) 
Annual healing Major amputation n (%) Annual major amputation rate 
Apelqvist 2011 (12) 
 
1151 DFU 
 602 (72) 
(percentage calculated 
based on 836 patients 
alive, 310 died with ulcer 
present) 
..... 143 (12) --- 
Elgzyri 2014 (13) 478 DFU 217 (45) 54% 76 (16) 19% 
Odds ratio for 
amputation 2.988 
(2.099,4.252) 
PLR 75, NLR 0.25 
(assuming specificity 
of 99%) 
Elgzyri 2013 (14) 
 
602 DFU 227 (38) 61% NS … 
Bunt 1996 
(24) 





DFU 25 (71) … 10 (29) … 






63 (66) … 33 (34) … 
Kalani 1999 
 (18) 
50 DFU 20 (40) 40% 4 (8) 8% 
Brechow 2013 (19) 
 










1617 (65) healing without 
minor amputation; 1867 
(75) including minor 
amputations 
… 193 (8) … 





NS … 34 (35) … 







DFU NS NS NS NS 
Fagher 2018 
(21) 
236 DFU 55 (23.1) at 3 months NS 19 (8.1) NS 
Jeon 2017 
(36) 







and III foot 
ulcers  
470/564=83% NS 
Major amputation (above 
ankle) 62/564=11% 
Not given. 
       
 
 
Table 4. Characteristics of Included Studies Evaluating PAD Measures for Healing 
Source N (DFU) 
Proportion 
Men (%) 
Age (years) mean 
(SD) or (Range) Population Index test RR PLR NLR 
Apelqvist 2011 (12) 1151 61 75 (40-92) DFU Measurable ankle pressure 1.12 (0.80-1.55) 1.02 0.86 
Elgzyri 2014 (13) 478 60 74 (IQR 66-80) DFU Intermittent claudication 1.25 (1.16-1.36) 1.59 0.81 
Elgzyri et al, 2013 
(14) 
 
602 60 76 (36-95) DFU Ankle pressure >50 mmHg 
 














147   Pedal sepsis Palpable pedal pulses 
 
Diminished/ absent pedal pulses 














32 68  DFU Toe pressure ≥ 30 mmHg:  
 
Ankle pressure ≥ 100 mmHg 
 























83   DFU OR 
gangrene 
Ankle pressure ≥ 70 mmHg 
 
Toe pressure ≥20 mmHg 
 


















50 74 61 (12) DFU TcPO2 ≥25 mmHg 
Toe pressure ≥30mmHg  


















678  64 (11) DFU ABI >0.9 and <1.3 2.02 (1.40-2.91) 2.61 0.92 
Faris 1985 
(20) 
61  72 (38-86) DFU or gangrene Skin perfusion pressure 
≥40mmHg 
NS 4.86 0.03 
Gershater 2008 
(15) 
2511 59 68 (15) DFU Ankle pressure ≥80mmHg 
 
Ankle pressure ≥50mmHg  
 
Toe pressure ≥45mmHg 
 























         
Wang 2016 





ABI group - 
pooled mean 
59.6; TcPO2 
group – pooled 
mean 70 
ABI group - pooled 
mean 60.7; TcPO2 
group – pooled mean 
69.67 
























236 69.9 76 (69-82) DFU TcPO2 >25mmHg  
 
2.98 (1.13-7.86) 1.21 0.33 
Jeon 2017 
(22) 






































Note: *Definition of PAD using same reference test varied; see Table 4; †In combination with ABPI <0.9; DM, diabetes mellitus; SD, standard 
deviation; PLR positive likelihood ratio; NLR, negative likelihood ratio; DUS, duplex ultrasound; DSA, digital subtraction angiography; dABPI, 
doppler ankle brachial pressure index; oABPI, oscillometric ankle brachial pressure index; TBI, toe brachial index; PN+, with peripheral 
neuropathy; PN-, without peripheral neuropathy; NS, not stated; NA, not applicable (cannot be calculated). 
 
 
Table 5. Characteristics of Included Studies Evaluating PAD Measures for Major Amputation 




mean (SD) or 
(Range) Population Index test RR PLR NLR 
Wallin 1989 
(25) 
83   DFU OR 
gangrene 
Ankle pressure < 70 mmHg 
 
Toe pressure < 20 mmHg 
 


















678  64 (11) DFU ABI<0.5 or ankle pressure <50mmHg 25.00 (13.5-41.92) 8.24 0.14 
Gershater 2008 
 








(15) Ankle pressure <50mmHg 
 
Toe pressure <45mmHg 
 
















Tsai 2013 (17) 
 
97 55 65 (3) DFU AND 
dialysis 
Poor monophasic waveform or 
absence of flow in below knee vessels 













ABI group - 
pooled mean 
60.7; TcPO2 
group – pooled 
mean 69.67 
























236 69.9 76 (69-82) DFU TcPO2 ≤25mmHg 5.53 (2.36-12.97) 3.41 0.51 
Jeon 2017 
(22) 



























Note: *Definition of PAD using same reference test varied. 
†In combination with ABPI <0.9; DM indicates diabetes mellitus; SD, standard deviation; PLR positive likelihood ratio; NLR, negative 
likelihood ratio; DUS, duplex ultrasound; DSA, digital subtraction angiography; dABPI, doppler ankle brachial pressure index; oABPI, 
oscillometric ankle brachial pressure index; TBI, toe brachial index; PN+, with peripheral neuropathy; PN-, without peripheral 
neuropathy; NS, not stated; NA, not applicable (cannot be calculated). 
 
 
 
 
 
